一个家族性多囊肾伴纤维蛋白原缺陷症家系的基因诊断、临床特征及文献回顾
收稿日期: 2023-03-09
网络出版日期: 2024-01-25
基金资助
国家自然科学基金项目(82170128)
Genetic diagnosis and clinical analysis of congenital dysfibrinogenemia with polycystic disease: a case report and literature review
Received date: 2023-03-09
Online published: 2024-01-25
周礼扬, 张春丽, 丁秋兰, 李娅 . 一个家族性多囊肾伴纤维蛋白原缺陷症家系的基因诊断、临床特征及文献回顾[J]. 内科理论与实践, 2023 , 18(05) : 328 -333 . DOI: 10.16138/j.1673-6087.2023.05.004
Key words: Dysfibrinogenemia; Fibrinogen; Polycystic disease; Gene mutation
[1] | Dell KM, Matheson M, Hartung EA, et al. Kidney disease progression in autosomal recessive polycystic kidney disease[J]. J Pediatr, 2016, 171: 196-201. |
[2] | Bergmann C, Guay-Woodford LM, Harris PC, et al. Polycystic kidney disease[J]. Nat Rev Dis Primers, 2018, 4(1):50. |
[3] | Harris PC, Torres VE. Polycystic kidney disease, autosomal dominant[DB/OL]. 2022. https://www.ncbi.nlm.nih.gov/books/NBK1246/. |
[4] | Lanktree MB, Chapman AB. New treatment paradigms for ADPKD: moving towards precision medicine[J]. Nat Rev Nephrol, 2017, 13(12): 750-768. |
[5] | Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease[J]. Lancet, 2019, 393(10174): 919-935. |
[6] | Neerman-Arbez M, de Moerloose P, Casini A. Laboratory and genetic investigation of mutations accounting for congenital fibrinogen disorders[J]. Semin Thromb Hemost, 2016, 42(4): 356-365. |
[7] | Richard M, Celeny D, Neerman-Arbez M. Mutations accounting for congenital fibrinogen disorders[J]. Semin Thromb Hemost, 2022, 48(8): 889-903. |
[8] | Casini A, Neerman-Arbez M, Ari?ns RA, et al. Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management[J]. J Thromb Haemost, 2015, 13(6): 909-919. |
[9] | Casini A, Blondon M, Lebreton A, et al. Natural history of patients with congenital dysfibrinogenemia[J]. Blood, 2015, 125(3): 553-561. |
[10] | Mangolini A, de Stephanis L, Aguiari G. Role of calcium in polycystic kidney disease[J]. World J Nephrol, 2016, 5(1): 76-83. |
[11] | Harris PC, Torres VE. Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease[J]. J Clin Invest, 2014, 124(6): 2315-2324. |
[12] | Bergmann C. Recent advances in the molecular diagnosis of polycystic kidney disease[J]. Expert Rev Mol Diagn, 2017, 17(12): 1037-1054. |
[13] | Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal-dominant polycystic kidney disease (ADPKD)[J]. Kidney Int, 2015, 88(1): 17-27. |
[14] | Obeidova L, Elisakova V, Stekrova J, et al. Novel mutations of PKD genes in the Czech population with autosomal dominant polycystic kidney disease[J]. BMC Med Genet, 2014, 15: 41. |
[15] | Trujillano D, Bullich G, Ossowski S, et al. Diagnosis of autosomal dominant polycystic kidney disease using efficient PKD1 and PKD2 targeted next-generation sequencing[J]. Mol Genet Genomic, 2014, 2(5): 412-421. |
[16] | Rahbari-Oskoui F, Williams O, Chapman A. Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease[J]. Nephrol Dial Transplant, 2014, 29(12): 2194-2201. |
[17] | Nauli SM, Jin X, Hierck BP. The mechanosensory role of primary cilia in vascular hypertension[J]. Int J Vasc Med, 2011: 376281. |
[18] | Kocyigit I, Eroglu E, Gungor O. Clinical problems in hemodialysis patients with autosomal dominant polycystic kidney disease[J]. Semin Dial, 2018, 31(3): 268-277. |
[19] | Rozenfeld MN, Ansari SA, Shaibani A, et al. Should patients with autosomal dominant polycystic kidney disease be screened for cerebral aneurysms?[J]. AJNR Am J Neuroradiol, 2014, 35(1): 3-9. |
[20] | Perrone RD, Malek AM, Watnick T. Vascular complications in autosomal dominant polycystic kidney disease[J]. Nat Rev Nephrol, 2015, 11(10): 589-598. |
[21] | Etminan N, Rinkel GJ. Unruptured intracranial aneurysms: development, rupture and preventive management[J]. Nat Rev Neurol, 2016, 12(12): 699-713. |
[22] | Cagnazzo F, Gambacciani C, Morganti R, et al. Intracranial aneurysms in patients with autosomal dominant polycystic kidney disease: prevalence, risk of rupture, and management[J]. Acta Neurochir (Wien), 2017, 159(5): 811-821. |
[23] | Qian Q, Younge BR, Torres VE. Retinal arterial and venous occlusions in patients with ADPKD[J]. Nephrol Dial Transplant, 2007, 22(6): 1769-1771. |
[24] | Kuo IY, Chapman AB. Polycystins, ADPKD, and cardiovascular disease[J]. Kidney Int Rep, 2019, 5(4): 396-406. |
[25] | Gabow PA, Duley I, Johnson AM. Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease[J]. Am J Kidney Dis, 1992, 20(2): 140-143. |
[26] | Colbert GB, Elrggal ME, Gaur L, et al. Update and review of adult polycystic kidney disease[J]. Dis Mon, 2020, 66(5): 100887. |
[27] | Nishiura JL, Neves RF, Eloi SR, et al. Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients[J]. Clin J Am Soc Nephrol, 2009, 4(4): 838-844. |
[28] | Torres VE, Wilson DM, Hattery RR, et al. Renal stone disease in autosomal dominant polycystic kidney disease[J]. Am J Kidney Dis, 1993, 22(4): 513-519. |
[29] | Gambaro G, Fabris A, Puliatta D, et al. Lithiasis in cystic kidney disease and malformations of the urinary tract[J]. Urol Res, 2006, 34(2): 102-107. |
[30] | Moist LM, Churchill DN, House AA, et al. Regular monitoring of access flow compared with monitoring of venous pressure fails to improve graft survival[J]. J Am Soc Nephrol, 2003, 14(10): 2645-2653. |
[31] | Schwab SJ, Oliver MJ, Suhocki P, et al. Hemodialysis arteriovenous access: detection of stenosis and response to treatment by vascular access blood flow[J]. Kidney Int, 2001, 59(1): 358-362. |
[32] | Hsieh MY, Cheng CH, Chen CH, et al. The association of long-term blood pressure variability with hemodialysis access thrombosis[J]. Front Cardiovasc Med, 2022, 9:881454. |
[33] | Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia[J]. Thromb Haemost, 1995, 73(1): 151-161. |
[34] | Casini A, How I treat dysfibrinogenemia[J]. Blood, 2021, 138(21): 2021-2030. |
[35] | Vakalopoulou S, Mille-Baker B, Mumford A, et al. Fibrinogen Bbeta14 Arg—>Cys: further evidence for a role in thrombosis[J]. Blood Coagul Fibrinolysis, 1999, 10(7): 403-408. |
/
〈 |
|
〉 |